R398
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 3
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.480
- ALLOGRAFT_REJECTION+0.460
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.460
- G2M_CHECKPOINT+0.460
- MYC_TARGETS_V2+0.460
- INTERFERON_ALPHA_RESPONSE+0.420
- INTERFERON_GAMMA_RESPONSE+0.410
- MYC_TARGETS_V1+0.410
- MITOTIC_SPINDLE+0.370
- IL6_JAK_STAT3_SIGNALING+0.350
Top 10 suppressed
- PROTEIN_SECRETION-0.260
- BILE_ACID_METABOLISM-0.200
- PEROXISOME-0.120
- KRAS_SIGNALING_DN-0.110
- PANCREAS_BETA_CELLS-0.050
- XENOBIOTIC_METABOLISM-0.040
- SPERMATOGENESIS+0.010
- HEME_METABOLISM+0.020
- UV_RESPONSE_DN+0.040
- NOTCH_SIGNALING+0.060
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-66-2765-01A-01R-0851-07 | — | cohortSQ1 | 0.892 |
| 2 | AF0A7BAA-D031-4C9F-91B7-7034F2C49D72 | — | — | 0.892 |
| 3 | TCGA-G2-A2ES-01A-11R-A180-07 | — | — | 0.889 |
| 4 | TCGA-EW-A1P4-01A-21R-A144-07 | — | E | 0.885 |
| 5 | 6e639239-cdae-4412-880f-ef813a956ff7 | — | — | 0.884 |
| 6 | SRR1516056 | — | — | 0.880 |
| 7 | SRR1516055 | — | — | 0.877 |
| 8 | 795FBB8C-0E74-477F-AA27-1CE97A4E90B9 | — | — | 0.875 |
| 9 | 81B10E10-884A-46EB-9F28-758D805FB9B1 | — | — | 0.873 |
| 10 | TCGA-XF-A9T8-01A-11R-A39I-07 | — | — | 0.870 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 44 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.480 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.460 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.460 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.460 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.460 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.420 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.410 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.410 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.370 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.350 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.340 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.330 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.320 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.320 | Idelalisib | — uncovered |
| COMPLEMENT | 0.290 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.280 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.260 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.250 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.240 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.230 | Inavolisib | — uncovered |